KRAS G12C inhibitors in KRASG12C-mutated solid tumors: an immunologically informed systematic review and reconstructed individual patient data meta-analysis - Scorecard - MDSpire
Advertisement
KRAS G12C inhibitors in KRASG12C-mutated solid tumors: an immunologically informed systematic review and reconstructed individual patient data meta-analysis
Clinical Scorecard: Systematic Review and Meta-Analysis of Individual Patient Data on KRAS G12C Inhibitors in Solid Tumors with KRAS G12C Mutations: Insights from Immunological Perspectives
At a Glance
Category
Detail
Condition
KRAS G12C Mutations in Solid Tumors
Key Mechanisms
Inhibition of KRAS G12C leads to improved progression-free survival and objective response rates, with immune modulation via PD-L1 expression.
Target Population
Patients with solid tumors harboring KRAS G12C mutations, particularly older patients, those without liver metastases, or those with PD-L1 < 50%.
Care Setting
Oncology clinical trials and treatment settings.
Key Highlights
KRAS G12Ci demonstrated better progression-free survival (HR, 0.62; P < 0.001) compared to standard care.
No significant difference in overall survival (HR, 0.93; P = 0.495) was observed.
Objective response rate for KRAS G12Ci was 3.60 (P < 0.001).
PFS benefits were noted in patients with PD-L1 expression <1% and 1%-49%.
KRAS G12Ci showed a superior safety profile, with exceptions for diarrhea and rash.
Guideline-Based Recommendations
Diagnosis
Confirm KRAS G12C mutation status in patients with solid tumors.
Management
Consider KRAS G12Ci for later-line therapy in appropriate patient populations.
Monitoring & Follow-up
Monitor progression-free survival and adverse events during treatment.
Risks
Be aware of potential adverse effects, including diarrhea and rash.
Patient & Prescribing Data
Patients with solid tumors, particularly non-small cell lung cancer and colorectal cancer, with KRAS G12C mutations.
KRAS G12Ci may be more effective in patients with lower PD-L1 expression levels.
Clinical Best Practices
Utilize individual patient data meta-analysis for assessing treatment efficacy.
Incorporate PD-L1 expression levels in treatment decision-making.
